Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.

Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi J, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M; NPC-08 study group.

Neurol Med Chir (Tokyo). 2014;54(4):290-301. Epub 2013 Nov 29.

2.

A Multicenter Phase I/II Study of the BCNU Implant (Gliadel® Wafer) for Japanese Patients with Malignant Gliomas.

Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi JI, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M.

Neurol Med Chir (Tokyo). 2013 Nov 29. [Epub ahead of print]

3.

[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].

Yoshida M, Yamaguchi S, Ishi Y, Endo S, Motegi H, Kobayashi H, Asaoka K, Kamoshima Y, Terasaka S, Houkin K.

No Shinkei Geka. 2015 Jul;43(7):603-10. doi: 10.11477/mf.1436203084. Japanese.

PMID:
26136324
4.

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.

Bock HC, Puchner MJ, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A.

Neurosurg Rev. 2010 Oct;33(4):441-9. doi: 10.1007/s10143-010-0280-7. Epub 2010 Aug 13.

6.

Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.

Sai K, Zhong MG, Wang J, Chen YS, Mou YG, Ke C, Zhang XH, Yang QY, Lin FH, Guo CC, Chen ZH, Zeng J, Lv YC, Li X, Gao WC, Chen ZP.

J Neurol Sci. 2014 Aug 15;343(1-2):60-5. doi: 10.1016/j.jns.2014.05.022. Epub 2014 May 17.

PMID:
24874252
7.

The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.

Nagpal S.

Neurosurg Clin N Am. 2012 Apr;23(2):289-95, ix. doi: 10.1016/j.nec.2012.01.004. Epub 2012 Feb 18. Review.

PMID:
22440872
8.

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.

Westphal M, Ram Z, Riddle V, Hilt D, Bortey E; Executive Committee of the Gliadel Study Group.

Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275. Epub 2006 Feb 17.

PMID:
16482400
9.

Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.

Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, Olivi A, Wharam MD, Brem H.

Cancer Invest. 2004;22(1):1-9.

PMID:
15069758
10.

Risk management in the treatment of malignant gliomas with BCNU wafer implants.

Giese A, Bock HC, Kantelhardt SR, Rohde V.

Cent Eur Neurosurg. 2010 Nov;71(4):199-206. doi: 10.1055/s-0029-1242775. Epub 2010 Jan 8. Review.

PMID:
20063259
11.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

12.

Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.

Chowdhary SA, Ryken T, Newton HB.

J Neurooncol. 2015 Apr;122(2):367-82. doi: 10.1007/s11060-015-1724-2. Epub 2015 Jan 29.

13.

Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.

Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H.

Ann Surg Oncol. 2008 Oct;15(10):2887-93. doi: 10.1245/s10434-008-0048-2. Epub 2008 Jul 18.

PMID:
18636295
15.

Incorporating BCNU wafers into malignant glioma treatment: European case studies.

Balossier A, Dörner L, Emery E, Heese O, Mehdorn HM, Menei P, Singh J.

Clin Drug Investig. 2010;30(3):195-204. doi: 10.2165/11532900-000000000-00000.

PMID:
20155992
16.

Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.

Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S; New Approaches to Brain Tumor Therapy CNS Consortium.

J Clin Oncol. 2003 May 1;21(9):1845-9.

PMID:
12721262
17.

Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation--incidence, therapeutic strategies, and outcome.

Dörner L, Ulmer S, Rohr A, Mehdorn HM, Nabavi A.

J Clin Neurosci. 2011 Mar;18(3):347-51. doi: 10.1016/j.jocn.2010.05.036. Epub 2011 Jan 14.

PMID:
21237660
18.

Chemotherapy wafers for high grade glioma.

Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K.

Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007294. doi: 10.1002/14651858.CD007294.pub2. Review.

PMID:
21412902
19.
20.

Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.

Miglierini P, Bouchekoua M, Rousseau B, Hieu PD, Malhaire JP, Pradier O.

Clin Neurol Neurosurg. 2012 Nov;114(9):1222-5. doi: 10.1016/j.clineuro.2012.02.056. Epub 2012 Mar 31.

PMID:
22464950

Supplemental Content

Support Center